

- 15.00-15.10 Combination of MRI-based parameters with MR/US-fusion targeted biopsy-proven risk-factors may improve staging of prostate cancer. T. Matsugasumi E. Baco, E. Suen, J. C. Bernhard, R. Azhar, A. L. de Castro Abreu, I. S. Gill, **O. Ukimura** (*Los Angeles, USA; Oslo, N*)
- 15.13-15.23 The role of early repeated biopsies with MRI-ultrasound fusion system in the selection process of patients eligible for Active Surveillance after a first TRUS-guided 12 biopsies scheme. A single-center prospective study. **E. Potiron**, J. Lacoste, T. Rousseau, G. Ille Goguic, G. Aillet, P. Nevoux (*Nantes, F*)
- 15.26-15.36 Innovations in prostate biopsy strategies for active surveillance and focal therapy. **K. Mammen** (*Ludhiana, India*)
- 15.39-15.49 Novel 3D-mapping biopsy techniques (including both re-visiting to target the previous positive trajectory and systematic field biopsy to target the previously negative field for cancer) for active surveillance and focal therapy. **O. Ukimura** (*Los Angeles, USA*)
- 15.52-16.02 Incidence of organ-confined prostate cancer with unilateral pattern of Gleason <= 3 + 4 suitable for focal therapy  
F. Bertolotto, F. Germinale, M. Raggio, **P. Puppo** (*Genoa, Imperia, I*)
- 16.05-16.15 Shear wave elastography for localization of prostate cancer lesions and assessment of elasticity thresholds: Implications for targeted biopsies and active surveillance protocols. **L. Budaeus** (*Hamburg, D*)
- 16.18-16.28 Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer. **F. Cornud** (*Paris, F*)
- 16.31-16.41 Focal HIFU treatment of localized prostate cancer diagnosed and controlled with MRI-ultrasound fusion targeted biopsies : preliminary results. **E. Potiron**, J. Lacoste, T. Rousseau, G. Le Goguic, G. Aillet, P. Nevoux (*Saint Herblain, Nantes, F*)
- 16.44-16.54 Real-time transrectal ultrasonography-guided hands-free technique for focal cryoablation of the prostate. **O. Ukimura** (*Los Angeles, USA*)
- 17.00-17.30 Panel discussion: **NO MORE AS OR FOCAL THERAPY WITH "OLD FASHIONED" BIOPSY?**
- 17.30 Closing remarks

## Faculty

**E. Baco** (*Oslo, N*) • **F. Bertolotto**, (*Imperia, I*) • **B. Beyer** (*Hamburg, D*) • **L. Budaeus** (*Hamburg, D*) • **F. Cornud** (*Paris, F*) • **A. Fandella** (*Monastier di Treviso, I*) • **M. Ferriero** (*Rome, I*) • **R. Galli** (*Modena, I*) • **A. Giacobbe** (*Turin, I*) • **B. A. Hadaschik** (*Heidelberg, D*) • **B. Malavaud** (*Toulouse, F*) • **K. Mammen** (*Ludhiana, India*) • **S. McRae** (*Houston, USA*) • **P. Mozer** (*Paris, F*) • **V. Panebianco** (*Rome, I*) • **J. M. Pina** (*Lisbon, P*) • **S. Polanec** (*Wien, A*) • **E. Potiron** (*Nantes, F*) • **P. Puppo** (*Genoa, I*) • **V. Scattoni** (*Milan, I*) • **T. Shin** (*Yufu-shi, Oita, J*) • **G. Simone** (*Turin, I*) • **S. Takahata** (*Tokyo, J*) • **O. Ukimura** (*Los Angeles, USA*)

## CONFERENCE VENUE

**HOTEL MELIÀ ROMA AURELIA ANTICA**  
Via degli Aldobrandeschi, 223 – 00163 Roma  
Tel. + 39 06 665441  
E-mail: melia.roma@melia.com  
www.melia.com

## LANGUAGE

The official language of the conference is English. No simultaneous translation will be provided.

## REGISTRATION INFO

Written requests via fax or email must be sent to the Organizing Secretariat in order to register for the Conference together with the copy of the registration fee payment. Upon receipt of the registration and the required payment, a written confirmation and an invoice will be sent by e-mail. The numbers for the conference are limited; registrations will be accepted within and not later than 10 January 2015 on first come, first served basis therefore on site registrations will not be guaranteed. Registrations not accompanied by the relevant payment will not be accepted.

## Registration fee (VAT 22% included)

**Euro 244,00** (not applicable for published work presenters)

The registration fee includes: admission to scientific sessions, lunch & coffee break, delegate's bag, certificate of attendance.

## Registration fees must be paid only in Euro (€) by the following methods:


- Bank transfer to Synthesis S.r.l.  
Cassa di Risparmio di Savona S.p.A.  
IBAN IT31S0631049320000000781080  
SWIFT CODE CRSVIT2S117  
reason: registration Consensus Biopsy Rome 2015  
Important: all bank charges are to be borne by the transmitter.
- Cheque made out to: Synthesis S.r.l. to be sent to:  
Synthesis S.r.l., Via S.M.G. Rossello, 24 – 17027 Pietra Ligure (SV).

## CERTIFICATE OF ATTENDANCE

The certificate of attendance will be issued to all registered participants on request at the Organizing Secretariat desk after h. 10.00 a.m. on 24 January 2015.

## HOW TO REACH CONFERENCE VENUE

The Melià Roma Aurelia Antica Hotel, is located just minutes from the Via Aurelia and the Ring Road (exit Aurelia-Vatican City) in a green and quiet area, not far from the Fiumicino Airport (22 km), from Ciampino Airport (26 km), from the Termini railway station (11 km) and a few kilometers from Piazza San Pietro, Castel Sant'Angelo and the Vatican Museums.



## ORGANIZING SECRETARIAT

**SYNTHESIS S.r.l.**  
Via S.M.G. Rossello, 24  
17027 Pietra Ligure (SV)  
Tel./Fax +39 019 626485  
E-mail synthesis@uinet.it

# Paradigm shift in prostate cancer diagnosis: how new standards arise from image- based technologies



January 23-24  
**Rome - Italy**

## International challenge conference on MRI and biopsy in the diagnosis of prostate cancer

### Scientific Chairman

P. Puppo (*Genoa, I*)

### Scientific Board

E. Baco (*Oslo, N*)  
L. Budaeus (*Hamburg, D*)  
F. Cornud (*Paris, F*)  
M. Gallucci (*Rome, I*)  
B. Malavaud (*Toulouse, F*)  
P. Mozer (*Paris, F*)  
V. Panebianco (*Rome, I*)  
O. Ukimura (*Los Angeles, USA*)

### Scientific Secretariat

F. Bertolotto (*Imperia, I*)  
A. Fandella (*Monastier di Treviso, I*)  
M. Ferriero (*Rome, I*)

# PROGRAM

Friday, January 23

- 14.00 **WELCOME AND INTRODUCTION - P. Puppo**
- 14.30-16.00 PROSTATE MAPPING WITH OR WITHOUT TRACKING: FROM FICTION TO FACT ?**  
Chairmen: **B. Malavaud, P. Mozer**
- 14.30-14.45 Maximum performance of conventional and saturation prostate mapping **V. Scattoni** (Milan, I)
- 14.45-15.00 Detection rate in a French series of prostate mapping. **B. Malavaud** (Toulouse, F)
- 15.00-15.15 The correspondence between conventional and 3D controlled mapping. **P. Mozer** (Paris, F)
- 15.15-15.30 Detection rate of stereotactic prostate mapping with needle tracking and virtual simulator  
F. Bertolotto, **P. Puppo**, M. Raggio, F. Germinale (Genoa, Imperia, I)
- 15.30-15.45 2D-US versus 3D-US guided saturation biopsy to detect prostate cancer. **M. Ferriero**, G. Simone, R. Papalia, R. Mastroianni, S. Guaglianone, M. Gallucci (Rome, I)
- 15.45-16.00 Discussion
- 16.00-16.30 PANEL: ARE WE STILL ALLOWED TO PERFORM PROSTATE MAPPING WITHOUT 3D TRACKING SYSTEM?**
- 16.30-17.00 Coffee break
- 17.00-18.30 THE VALUE OF MULTIPARAMETRIC MRI IN THE WORK-UP OF PROSTATE CANCER DIAGNOSIS**  
Chairmen: **F. Cornud, V. Panebianco**
- 17.00-17.20 Actual performances of 1.5 and 3 tesla MRI in the diagnosis of prostate cancer. **V. Panebianco** (Rome, I)
- 17.20-17.35 MRI visualization of the anterior part of the prostate. **E. Baco** (Oslo, N)
- 17.35 -17.45 The use of MRI prior prostate biopsy in a tertiary care centre: A plea for standardization. **B. Beyer**, S. R. Leyh Bannurah, H. Heinzer, A. Haese, M. Graefen, L. Budaeus (Hamburg, D)
- 17.45-18.00 The Pirads system. **F. Cornud** (Paris, F)
- 18.00-18.10 Clinical significance of the absence of MRI target  
F. Bertolotto, **P. Puppo** (Imperia, Genoa, I)
- 18.10-18.30 Discussion

## 18.30-19.15 KEYNOTE LECTURES

Chairmen: **L. Budaeus, M. Gallucci**

12 ' + 3 ' discussion

- 18.30-18.45 Indications for MRI and biopsy under dutasteride treatment.  
**A. Fandella** (Monastier di Treviso, I)
- 18.45-19.00 Infective complications after standard TRUS and MRI/TRUS image fusion guided targeted prostate biopsies. Fewer biopsy cores may not mean fewer infections. **E. Baco** (Oslo, N)
- 19.00-19.15 Lymph node metastases in prostate cancer patients – Size, extension and implications for radiological imaging based on 6804 lymph nodes.  
**B. Beyer**, C. Meyer, S. R. Leyh Bannurah, G. Salomon, M. Graefen, L. Budaeus (Hamburg, D)

Saturday, January 24

## 08.30-12.40 BIOPSY AFTER MRI : COGNITIVE , FUSION, IN BORE TARGETING

Chairmen: **E. Baco, F. Cornud**

- 08.30-08.40 Comparing cognitive fusion with randomized prostate biopsies. The value of Multiparametric Prostatic MRI in the detection of cancer. **J. M. Pina**, J. L. Dias, L. Campos Pinheiro (Lisbon, P)
- 08.40-08.50 Multiparametric MRI followed by targeted prostate biopsy for men at second biopsy: a clinical decision analysis. **A. Fandella** (Monastier di Treviso, I)
- 08.50-09.00 **Discussion: Cognitive**
- 09.00 -09.10 Multiparametric MRI in Biopsy Guidance for Prostate Cancer: Fusion Guided. **K. Mammen** (Ludhiana, India)
- 09.10-09.25 MRI-targeted fusion biopsies: transperineal approach. **B. A. Hadaschik** (Heidelberg, D)
- 09.25-09.35 Clinical application of targeted stereotactic prostate biopsy: preliminary experience in our center. **R. Galli**, E. Martorana, A. Zordani, A. Ghaith, M. Paterlini, S. Micali, G. Bianchi (Modena, I)
- 09.35-09.45 New biopsy method of prostate using fusion guided imaging, MRI and real-time TRUS images. **S. Takahata**, Y. Wakumoto, A. Tsujumura, S. Hisasue, D. Nozaki, F. Shimizu, K. Terai, H. Aoki, S. Shiozawa, T. China, T. Ieda, T. Ashizawa, N. Nagaya, Y. Aoki, S. Horie (Tokyo, J)
- 09.45-09.55 Initial experience of transperineal targeted prostate biopsy using real time magnetic resonance imaging (MRI) and transrectal ultrasound (TRUS) image fusion. **T. Shin**, H. Fujinami, T. Narimatsu, F. Sato, H. Mimata (Yufu-shi, Oita, J)

- 09.55 – 10.10 Discussion: fusion, transperineal
- 10.10 -10.30 Coffee break
- 10.30 -10.40 MRI-ultrasound fusion targeted biopsies (KOELIS). A Single-center prospective study. **E. Potiron**, P. Nevoux, T. Rousseau, G. Le Goguic, G. Aillet, J. Lacoste (Nantes, F)
- 10.40-10.50 3D US versus US/MRI fusion-guided target biopsy to detect prostate cancer: a preliminary experience. **M. Ferriero**, G. Simone, R. Papalia, S. Guaglianone, M. Gallucci (Rome, I)
- 10.50 -11.00 Ultrasound/MRI fusion vs. systematic 12-core prostate rebiopsy: preliminary experience. **A. Giacobbe**, G. Simone, D. Collura, E. Castelli, R. Rosso, G. L. Muto, L. D'Urso, G. Muto. (Turin, I)
- 11.00 -11.10 Diagnostic performance of multiparametric MRI in prostate cancer: per core analysis of two prospective ultrasound/MRI fusion biopsy datasets. **G. Simone**, A. Giacobbe, D. Collura, R. Papalia, S. Guaglianone, G. L. Muto, M. Gallucci, G. Muto, M. Ferriero. (Turin, Rome, I)
- 11.10 -11.25 **Discussion: Fusion, transrectal**
- 11.25-11.35 Detection of significant prostate cancer with MR-targeted biopsies: Should TRUS-MRI fusion guided biopsies alone be a standard of care? N. B. Delongchamps. A. Lefèvre, N. Bouazza, F. Beuvon, P. Legman, **F. Cornud** (Paris, F)
- 11.35-11.45 Sensitivity, specificity, PPV / NPV of MRI “target” with targeted “fusion biopsy”  
F. Bertolotto, F. Germinale, M. Raggio, **P. Puppo** (Genoa, Imperia, I)
- 11.45-12.00 **Discussion: MRI targeted only?**
- 12.00 -12.10 Magnetic resonance imaging-guided prostate biopsy in a patients cohort with previous suspicious MRI to rule out Prostate cancer.  
**S. Polanec**, K. Pinker, M. Susani, P. Brader, T. Helbich, P. Baltzer (Wien, A)
- 12.10-12.25 Transgluteal in-bore MR guided prostate biopsy for patients with transrectal ultrasound (TRUS) biopsy findings that are discordant with PSA level. S. Sabir, **S. McRae**, K. Ahrar, H. Choi, J. Ward - (Houston, USA)
- 12.25 -12.40 Discussion: in bore
- 12.40-14.00 Work lunch
- 14.00-15.00 PANEL: DO WE NEED NEW GUIDELINES FOR PROSTATE BIOPSY?**  
Chairman: **A. Fandella**  
Panelists: **B. Malavaud, P. Mozer, B. Hadaschik**
- 15.00-17.00 THE IDEAL BIOPSY FOR ACTIVE SURVEILLANCE AND FOCAL THERAPY**  
Chairmen: **P. Puppo, O. Ukimura**  
3 ' discussion after each lecture